Genetic testing company 23andMe is facing a class action lawsuit after users’ data was accessed without authorization – a breach it blames on customers who used a recycled password as login credentials for their account on the home DNA firm’s website. 23andMe wrote in a letter responding to attorneys representing customers whose data was exposed that no breach occurred under the provisions of the California Privacy Rights Act because users targeted in the initial breach were using login credentials that had ...

23andMe Holding Co. (NASDAQ:ME) Q2 2024 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Ian Cooney - Senior Director, IR Anne Wojcicki - Chief Executive Officer and Co-Founder Joseph Selsavage - Interim Chief Financial and Accounting Officer Jennifer Low - Head of Therapeutics Bill Richards - Head of Therapeutics Discovery Conference Call Participants Chad Wiatrowski - TD Cowen David Lebowitz - Citigroup Inc. Operator Hello, and welcome to 23andMe's Fiscal Year 2024 Second Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO___________ Commission File Number 001-39587 Delaware 87-1240344 (State or other jurisdiction of incorporation or organization) (I.R.S ...

23andMe Holding Co. (NASDAQ:ME) Q1 2024 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Katie Watson - Vice President of Communications Anne Wojcicki - Chief Executive Officer and Co-Founder Joe Selsavage - Interim Chief Financial and Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants David Lebowitz - Citi Gaurav Goparaju - Berenberg Capital Markets Operator Hello, and welcome to 23andMe’s Fiscal Year 2024 First Quarter Financial Results Confe ...

Table of Contents (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO___________ Commission File Number 001-39587 23ANDME HOLDING CO. (Exact name of Registrant as specified in its Charter) Delaware 87-1240344 ...

Financial Data and Key Metrics - Revenue for the 3 months ended March 31, 2023, was $92 million, a decrease of 8% year-over-year, while the 12-month revenue was $299 million, an increase of 10% year-over-year [45] - Consumer services revenue accounted for 88% and 83% of total revenue for the 3 and 12 months ended March 31, 2023, respectively, while research services revenue, primarily from the GSK collaboration, accounted for 12% and 17% respectively [47] - Net loss for the 3 and 12 months ended March 31, 2023, was $64 million and $312 million, respectively, compared to $70 million and $217 million in the prior year [50] - Adjusted EBITDA deficit for the 3 and 12 months ended March 31, 2023, was $39 million and $161 million, respectively, compared to $30 million and $151 million in the prior year [51] - The company ended the quarter with $387 million in cash and cash equivalents, down from $553 million as of March 31, 2022 [60] Business Line Data and Key Metrics - The consumer business saw a 10% year-over-year revenue growth in fiscal year 2023, driven by higher average selling prices on PGS kits and a 51% year-over-year growth in 23andMe+ subscription members, now totaling over 640,000 members [13][38] - The therapeutics business presented Phase 1/2a clinical data for 23ME-00610, an antibody targeting CD200R1, showing acceptable safety and tolerability profiles, with ongoing Phase 2a trials in multiple cancer types [24][25][26] - The company continues to integrate Lemonaid telehealth and pharmacy services with its genetic services, focusing on personalized healthcare and mental health services [21] Market Data and Key Metrics - The company has over 14 million genotype customers, an 11% year-over-year growth, creating the world's largest crowdsourced platform of genetic information paired with billions of phenotypic data points [36] - The Novartis collaboration aims to raise awareness for Lipoprotein(a), a genetic risk factor for cardiovascular disease, leveraging 23andMe's customer base and Lemonaid's telehealth capabilities [39][73] Company Strategy and Industry Competition - The company is prioritizing margin expansion and cash burn minimization over top-line growth in its consumer business, while continuing to invest in therapeutic assets [52][61] - The integration of Lemonaid services into the 23andMe app is planned, aiming to create a holistic experience for customers, combining genetic insights with telehealth and pharmacy services [95][105] - The company is actively seeking new partnerships and collaborations, particularly after the GSK target discovery exclusivity period ends in July 2023 [40][65] Management Commentary on Operating Environment and Future Outlook - Management highlighted the potential of combining genomics with telemedicine and pharmacy services to recruit new customers and engage existing ones, emphasizing the importance of mental health services [5][21] - The company expects to continue improving its adjusted EBITDA deficit in fiscal year 2024, driven by margin and operating expense discipline, with a projected adjusted EBITDA deficit of $170 million to $195 million [11][79] - The company is optimistic about leveraging AI to enhance its drug discovery and development processes, as well as automating business functions at scale [99][109] Other Important Information - The company increased subscription prices for 23andMe+ members, reflecting the additional benefits provided, and continues to focus on delivering premium insights and features [18][19] - The company is evaluating the use of its capital for both consumer and therapeutics businesses, including responsibly opting in and out of therapeutic programs based on market conditions [60][97] Q&A Session Summary Question: What is the expected burn rate for therapeutic spend in fiscal 2024, and when will the consumer business be EBITDA positive? - The therapeutic adjusted EBITDA deficit is approximately $23 million per quarter, with potential increases as drug development progresses [68] - The company does not have a specific date for when the consumer business will be EBITDA positive but is making meaningful progress toward that goal [85] Question: How will the Novartis collaboration on Lipoprotein(a) be monetized? - The collaboration leverages 23andMe's ability to educate and engage customers, with potential for follow-up testing and services through Lemonaid [73][88] Question: What is the plan for integrating Lemonaid services into the 23andMe app? - The company plans to integrate Lemonaid services into the 23andMe app, creating a holistic experience for customers that combines genetic insights, telehealth, and pharmacy services [95][105] Question: What is the long-run business outlook for 23andMe, and what are the plans to become profitable? - The company aims to continue improving margins and moving toward cash flow positive in the consumer business, while investing in therapeutic assets [108] Question: How is 23andMe planning to implement AI into its practices? - The company is leveraging AI in various areas, including drug discovery, automation, and enhancing customer engagement, with a focus on integrating AI into its personalized health offerings [99][109] Question: Will the company require a dilutive capital raise in the future? - The company is evaluating its capital needs and will be opportunistic in fundraising, with a focus on allocating capital to the best ROI for shareholders [101]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO___________ Commission File Number 001-39587 23ANDME HOLDING CO. (Exact name of Registrant as specified in its Charter) Delaware 87-1240344 (State or other jurisdic ...

23andMe Holding Co. (NASDAQ:ME) Q3 2022 Earnings Conference Call February 8, 2023 4:30 PM ET Company Participants Wade Walke - VP, Investor Relations Anne Wojcicki - CEO & Co-Founder Joe Selsavage - Interim CFO & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Daniel Grosslight - Citigroup Steven Mah - Cowen Gaurav Goparaju - Berenberg Operator Good day, and welcome to 23andMe's Fiscal Year 2023 Third Quarter Financial Results Conference Call. At a reminder, this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

23andMe Holding Co. (NASDAQ:ME) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Wade Walke - Vice President-Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse Steven Mah - Cowen Operator Good day, and thank you for standing by. Welcome to the 23andMe's Fiscal Year 2023 Second Quarter E ...